GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2009

Health Discovery Enters Deals with Abbott and Quest Diagnostics for Prostate Cancer Tests

  • Health Discovery (HDC) inked two separate agreements related to its prostate cancer diagnostic program. It has given Abbott the right to commercialize its gene-based tests for clinically significant prostate cancer.

    Abbott acquired coexclusive clinical laboratory rights and exclusive in vitro diagnostic rights for HDC’s tissue-based and urine-based prostate cancer test.

    Additionally, HDC licensed rights to Quest Diagnostics for the development of a urine-based test for clinically significant prostate cancer. Under the terms of this agreement, HDC will receive payments, royalties, and additional undisclosed financial considerations.

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?